

2002 Compugen Ltd

**Run on:**

## Sequencing

### Scoring

## Search

Total n

### Minimum

Post-mortem

### Command

-MODEL=f1

Database :

No.[illegible]

## ALIGNMENTS

AA  
AC  
AAND01120XX  
DE  
11-11-11

Human; O.

Homo sapiens

CDs



SULT 3  
190700

RESOL 3  
ABL90790

ID ABL90790 standard; cDNA: 1436 BP.  
XX ABL90790;  
AC  
XX 24-MAY-2002 (first entry)  
XX  
XX  
XX Human polynucleotide SEQ ID NO 1352.  
DE  
XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;  
XX antiallergic; hepatotropic; antidiabetic; antiinflammatory; antifungal;  
XX antitubercular; antibacterial; antifungal; antiparasitic;  
XX antiviral; anticonvulsant; anticancer; immune disorder; cardiovascular disorder;  
XX cardiac; gene therapy; cancer; immune disorder; cardiovascular disorder;  
XX neurological disease; infection; human; secreted protein; gene; ss.  
OS Homo sapiens.  
XX  
XX MO200190304-A2.  
XX  
XX 29-NOV-2001.  
XX  
XX 18-MAY-2001; 2001MO-US16450.  
XX  
XX 19-MAY-2000; 2000US-205515P.  
XX  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX  
XX Birse CE, Rosen CA;  
XX  
XX WPI; 2002-122018/16.  
XX  
XX P-PSDB; ABB90381.  
XX  
XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and  
XX prevention of neural, immune system, muscular, reproductive,  
XX gastrointestinal, pulmonary, cardiovascular, renal and proliferative  
XX disorders -  
XX  
XX Claim 4; SEQ ID NO 1352; 2081bp + sequence listing: English.  
XX  
XX The invention relates to novel genes (ABL89449-ABL90853) and proteins  
XX (ABB89040-ABB90444) useful for preventing, treating or ameliorating  
XX medical conditions e.g. by protein or gene therapy. The genes are  
XX isolated from a range of human tissues disclosed in the specification.  
XX The nucleic acids, proteins, antibodies and (ant)agonists are useful  
XX in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast  
XX and ovarian cancer and other cancers of the adrenal gland, bone, bone  
XX marrow, breast, gastrointestinal tract, liver, lung, or urogenital;  
XX (b) immune disorders e.g. Addison's disease, diabetes mellitus, Crohn's  
XX haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's  
XX disease, multiple sclerosis, rheumatoid arthritis and ulcerative  
XX colitis; (c) cardiovascular disorders such as myocardial ischaemia;  
XX (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and  
XX epilepsy; and (f) infectious diseases such as viral, bacterial, fungal  
XX and parasitic infections.  
XX Note: The sequence data for this patent did not form part of the  
XX printed specification, but was obtained in electronic format directly  
XX from WIPO at ftp.wipo.int/pub/published\_pcr\_sequences.  
XX  
XX Sequence 1436 BP; 397 A; 309 C; 289 G; 441 T; 0 other:  
SO

Alignment Scores:  
Pred. No.: 3 296-160 Length: 1436  
Score: 1737.00 Matches: 333  
Percent Similarity: 99.708 Conservative: 0  
Best Local Similarity: 99.708 Mismatches: 1  
Query Match: 99.438 Indels: 0  
DB: 24 Gaps: 0

US-09-765-034-2 (1-334) x ABL90790 (1-1436)

OY 1 MetLeuGlyIleMetAlaTrpAsnAlaIleThrCysLysAsnTrpLeuAlaIleAlaIle 20  
XX  
XX  
XX 93 ATGCTGGGAAATCATGATGCAATGCAAAATGCTGGAGCAGACAGAGGCTGCC 152  
Db

OY 21 LeuGlyIleTyrrLeuSerIlePheTyrrGlyIleGluPheValIleGlyValLeuGly 40  
XX  
XX 153 CTGGAAGAGTACTACCTTCATTTTATGCGATTGATGCTGGAGAGCTTGGA 212  
Db  
OY 41 AsnThrIleValIleValIleTyrrGlyIlePheSerLeuLysAsnTrpAsnSerSer 60  
XX  
XX 213 AATACCATGTTGTTTACGGCTACATCTCTCTGTAAGAACATGGAACACATTAAT 272  
Db  
OY 61 TyrrLeuPheAsnLeuSerValSerAspLeuAlaPheLeuGlySerThrLeuPromLeu 80  
XX  
XX 273 TATCTCTTTAACTCTCTGCTCTGACTTACTCTTCTGTCACCTCCCAAGCTGAT 332  
Db  
OY 81 ArgSerTyrrAlaAsnGlyAsnTrpIleTyrrGlyAspValLeuGlyIleSerAsnArg 100  
XX  
XX 333 AGGAGTTATGCCAATGGAACATGATATATGAGACGCTCTCATPAGAACCGAT 392  
Db  
OY 101 ValLeuHisAlaAsnLeuTyrrThrSerIleLeuPheLeuThrPheIleSerIleAsp 120  
XX  
XX 393 GTGCTTCATGCCAACCTCATACAGCATTCCTCTTCCACTTTATCAGCATGATCGA 452  
Db  
OY 121 TyrrLeuIleIleTyrrLeuPheArgGluHisLeuLeuGlnLysGluPheAlaIle 140  
XX  
XX 453 TACTGATATTAATTAATCTTCCGAGAACCTTCGCAAAAGAAAGATTGCTAT 512  
Db  
OY 141 LeuIleSerLeuAlaIleTrpValLeuValIleThrLeuGluLeuProIleLeuPro 160  
XX  
XX 513 TTAATCTCTTGGCATTTGGGTTTATGTAACCTTAAGATTACTACCATCTCCCT 572  
Db  
OY 161 IleAsnProValIleThrAspAsnGlyThrThrCysAsnAspPheAlaSerSerGly 180  
XX  
XX 573 ATAATCTCTTAACTGATGACATGACACCATGATTAATGATTTGCAATCTTGAG 632  
Db  
OY 181 ProAsnTyrrAsnLeuIleTyrrSerMetCysLeuThrLeuGluPheLeuPro 200  
XX  
XX 633 CCCAATCAACCACTTACAGATGCTGCTAACTGTGGGCTTCTTATCTCT 692  
Db  
OY 201 PheValMetCysPhePheTyrrLysIleAlaLeuPheLeuGlnArgGln 220  
XX  
XX 693 TTTGATGATGCTTCTTATTAACAGATTCCTCTCTTAAGAGAGAGATGAG 752  
Db  
OY 221 ValAlaThrAlaLeuProLeuGlnLysProLeuAsnLeuValIleMetAlaValIle 240  
XX  
XX 753 GTTGTACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 812  
Db  
OY 241 PheSerValProPheThrProTyrrHisValMetArgAsnValArgIleAsnArg 260  
XX  
XX 813 TTTCTGCTGCTTATACACCTATCAGCTCATGCGGATGAGATGAGATGAGCT 872  
Db  
OY 261 GlySerTrpLysGlnTyrrGlnCysThrGlnValValIleAsnSerPheTyrrIleVal 280  
XX  
XX 873 GGGAGTTGAAACCATATCAGTGCACCTGACCTGCTGCTGCTGCTGCTGCT 932  
Db  
OY 281 ArgProLeuAlaPheLeuAsnSerValIleAsnProValPheTyrrPheLeuGlyAsp 300  
XX  
XX 933 CGGCTTTGGCTTCTGCAAGTGTCAACACCTGCTCTTATTTCTTTGGGAT 992  
Db  
OY 301 HisPheArgAspMetLeuMetAsnGlnLeuArgHisAsnPheLysSerLeuThrSer 320  
XX  
XX 993 CACTTCAGGACATGCTGTATGATCACTGACGACACCACTCAATCCCTTACATCT 1052  
Db  
OY 321 SerArgTrpAlaHisGluLeuLeuLeuSerPheArgGlyLys 334  
XX  
XX  
XX 1053 AGCAGATGGGCTCATGATCCTGCTTATTCAGAGAAAG 1094  
Db  
RESULT 4  
AAD24958  
ID AAD24958 standard; cDNA: 1542 BP.  
XX  
XX AAD24958;  
XX  
XX 12-MAR-2002 (first entry)  
XX  
XX Human G-protein coupled receptor-3 (GCR3) cDNA.



```

XX 11-SEP-1997 (first entry)
DE Human purinergic receptor P2U2 cDNA.
XX P2U2 receptor; purinergic receptor; diagnosis; therapy; ss.
XX Homo sapiens.
XX Key location/Qualifiers
XX CDS 625..1629
XX FT /*tag= a
XX FT
XX MO9720045-A2.
XX 05-JUN-1997.
XX 08-NOV-1996; 96WO-0518175.
XX 15-NOV-1995; 95US-0559524.
XX 15-NOV-1995; 95US-0006782.
XX (COR-) COR THERAPEUTICS INC.
XX P-PSDB; AAW19854.
XX WPI; 1997-310601/28.
XX New isolated purinergic receptor sub-type - used to develop
XX products for diagnosis and therapy, e.g. for screening for agonists
XX and antagonists which can modulate activation
XX Claim 3; Fig 1A-C; 36pp; English.
XX A cDNA clone (AA71900) codes for a novel human purinergic receptor
XX subtype, designated P2U2 receptor (AAW19854), that is abundantly
XX expressed in kidney and in many cell lines of megakaryocytic or
XX erythroleukemic origin and which is activated by ATP, UDP, UTP and
XX UDP. The clone was obtd. by amplifying DMI (ATCC CRL 9792) cell
XX cDNA using primers (see also AA72104-05) based on transmembrane
XX regions of mouse P2u and chicken P2Y1 receptors, and use of the PCR
XX product to screen the DMI cDNA library to isolate the full-length
XX cDNA. P2U2 nucleic acids can be used in the recombinant prodn. of
XX P2U2 receptor polypeptides and as probes.
XX Sequence 1996 BP; 513 A; 454 C; 381 G; 647 T; 1 other:
XX
XX Alignment Scores:
XX Pred. No.: 7.57e-159 Length: 1996
XX Score: 1725.00 Matches: 331
XX Percent Similarity: 99.10% Conservative: 0
XX Best Local Similarity: 99.10% Mismatches: 3
XX Query Match: 98.74% Indels: 0
XX DB: 18 Gaps: 0
XX
XX US-09-765-034-2 (1-334) x AA71900 (1-1996)
XX
XX QY 1 MelLeuGlylleWetlAtRpAsnaIaThrCysLysAsnTrpLeuAlaIleGluAla 20
XX |
XX DB 625 ATGCTGGGATCATGGCAGATGCAACTGCAAAAATGCTGGCAGCAGAGCTTCC 684
XX
XX QY 21 LeuGluuYsTyrrTyreSerIlePheTyrglylleGluPheValValglyValleuGly 40
XX |
XX DB 685 CTGGAAGAAAGTACCTTCCATTTTATGGATTTGAGCTGGTGTGGAGTCTTGA 744
XX
XX QY 41 AsnThrIleValValTyrglyTyrrIlePheSerLeuLysAsnTrpAsnSerSeranle 60
XX |
XX DB 745 AATACCAATGTGTTCGCTACATCTTCTCTGAGAACTGCAAGCAGATATATT 804
XX
XX QY 61 TyrlauPheAsnLeuSerValSerAspLeuAlaPheLeuGlyThrleuPheIleuile 80
XX |
XX DB 805 TATCTCTTAACCTCTCTGCTCTGACTAGCTATGCTTTCTGTGCACCTCCCATGCTGATA 864

```

```

QY 81 ArgSerTyrrAlaasnGlyAsnTrpIleTyrglyAspValleuGlyIleSerAsnArgTyrr 100
XX |
DB 865 AGGAGTTATGTCATGAAATGGATATATGAGACGCTCTGCTGATAGCAACGATAT 924
XX
QY 101 ValLeuHisAlaAsnLeuTyrrThrSerIleLeuPheLeuThrPheIleSerIleAspArg 120
XX |
DB 925 GTGCTTATGCAACCTCTATACAGACATCTCTTCTCATCTTATATGCAATATGCA 984
XX
QY 121 TyrlleuIleIleTyrrProPheArgGluHisLeuLeuGlnLysGluPheAlaIle 140
XX |
DB 985 TACTTGATTAATTAAGTATCTTCCGGAACACCTTCTGCAAAAAGAAAGTTGCTATT 1044
XX
QY 141 LeuIleSerLeuAlaIleTrpValleuValThrLeuGluLeuLeuProIleLeuProIle 160
XX |
DB 1045 TTAATCTCTTGCCCATTTGGGTTTGTAGTAACTTAAGTTACTACCACTTCCCTT 1104
XX
QY 161 IleAsnProValIleThrAspAsnGlyThrThrCysAsnAspPheAlaSerSerGlyAsp 180
XX |
DB 1105 ATAAATCCGTATTAACAGACAAAGGACACACCTGTATATCTTTTGCAGTTCTGGAGAC 1164
XX
QY 181 ProAsnTyrrAsnLeuIleTyrrSerMetCysLeuThrLeuLeuGlyPheLeuIleProleu 200
XX |
DB 1165 CCAACTACAACTCTATTTACAGCATGTCTAACACAGTGGGGTCTTATTCCTCTT 1224
XX
QY 201 PheValMetCysPhePheTyrrTyrrIleAlaLeuPheLeuLysGlnArgAsnArgGln 220
XX |
DB 1225 TTTGTATGTGTTCTTTTATTAAGATGCTCTCTTCTTAAGCAGAGATATAGCAG 1284
XX
QY 221 ValAlaThrAlaLeuProLeuGlnLysProLeuAsnLeuValIleMetAlaValAlaIle 240
XX |
DB 1285 GTTGCTACCTCTGCTGCTTGAAGCCTTCAACTGTCATCATGAGAGTATC 1344
XX
QY 241 PheSerValProPheThrProTyrrHisValMetCysAsnValArgIleAlaSerArgLeu 260
XX |
DB 1345 TTCTCTGTCTTTTACACCTTACCTTACGCTACGCGAATGATGATGCTTACGCTG 1404
XX
QY 261 GlySerTrpLysGlnTyrrGlnCysThrGlnValValIleAsnSerPheTyrrIleValThr 280
XX |
DB 1405 GGGAGTTGAAAGCATGATCATGCTACAGTGTGCTATACCTTCTTACATTTGAC 1464
XX
QY 281 ArgProLeuAlaPheLeuAsnSerValIleAsnProValPheTyrrPheLeuGlnLysP 300
XX |
DB 1465 CGGGCTTTGGGCTTCTGAACAGTGTATATACCTCTCTCTATTTCTTTGGGAGAT 1524
XX
QY 301 HisPheArgAspMetLeuMetAsnGlnLeuArgHisAsnPheLysSerLeuThrSerPhe 320
XX |
DB 1525 CACTTCAGGACATGCTGATGAATCAACTGAGACAACTTCAATCCCTTACATCTTT 1584
XX
QY 321 SerArgTrpAlaHisGluLeuLeuLeuSerPheArgGlnLys 334
XX |
DB 1585 ACGAGATGGGCTCATGAACTCTTACTTTCATTCAGAGAAAG 1626
XX
XX RESULT 6
XX AAC81122
XX ID AAC81122 standard; cDNA; 1385 BP.
XX
XX AC AAC81122;
XX
XX AC 14-FEB-2001 (first entry)
XX
XX DE Human secreted protein gene 37 SMO ID NO:47.
XX
XX KW Human; secreted protein; diagnosis; immunosuppressive; antiarthritic;
XX antileukemic; antiproliferative; cytostatic; cardiast; vasotropic;
XX cerebroprotective; neuroprotective; antiinfective; antiviral;
XX fungicide; ophthalmological; valnerary; gene therapy; autoimmune disease;
XX hyperproliferative disorder; cardiovascular disorder; angiogenesis;
XX cerebrovascular disorder; nervous system disorder; infection; skin aging;
XX ocular disorder; wound healing; food additive; preservative; ss.
XX
XX Homo sapiens.
XX
XX OS
XX
XX

```

PN W0200061628-A1.  
 XX 19-OCT-2000.  
 PD 06-APR-2000; 2000OWO-US09070.  
 XX 09-APR-1999; 99US-0128695.  
 PF 14-JAN-2000; 2000US-0176052.  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PA Rosen CA, Ruben SM, Komatsoulis G;  
 XX WPI, 2000-619228/59.  
 DR P-PSDB; AAB45344.  
 XX New nucleic acid molecules encoding 49 human secreted proteins for  
 PT diagnosing, preventing, treating or ameliorating medical conditions and  
 PT used as food additives or preservatives -  
 PS Claim 1; Page 412; 454pp; English.  
 XX The polynucleotide sequences given in AAC81086 to AAC81134 encode the  
 CC human secreted proteins given in AAB45308 to AAB45356. AAB45357 to  
 CC AAB45384 represent human secreted polypeptide sequences and proteins  
 CC homologous to them, which are given in the exemplification of the present  
 CC invention. Human secreted proteins have activities based on the tissues  
 CC and cells the genes are expressed in. Examples of activities include:  
 CC antidiabetic; immunosuppressive; antineoplastic; antiproliferative;  
 CC cytoskeletal; cardiac; vasotropic; cerbroprotective; neurotropic;  
 CC neuroprotective; antibacterial; virucide; fungicide; ophthalmological;  
 CC and vulnerary. The polynucleotides and polypeptides can be used to  
 CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,  
 CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used  
 CC in diagnosing a pathological condition or susceptibility to a  
 CC pathological condition. Disorders which are diagnosed or treated include  
 CC autoimmune diseases, hyperproliferative disorders, cardiovascular  
 CC disorders, cerebrovascular disorders, angiodenesis, nervous system  
 CC disorders, infections caused by bacteria, viruses and fungi and ocular  
 CC disorders. The polypeptides can also be used to aid wound healing and  
 CC maintain organs before transplantation, for supporting cell culture of  
 CC primary tissues, to regenerate tissues and in chemotaxis. The  
 CC polypeptides can also be used as a food additive or preservative to  
 CC increase or decrease storage capabilities, fat content, lipid, protein,  
 CC carbohydrate, vitamins, minerals, cofactors and other nutritional  
 CC components. AAC81077 to AAC81085 and AAB45307 represent sequences used in  
 CC the exemplification of the present invention.  
 XX  
 SQ Sequence 1385 BP; 385 A; 296 C; 275 G; 429 T; 0 other:  
 Alignment Scores:  
 Pred. No.: 1 71e-157 Length: 1385  
 Score: 1709.00 Matches: 332  
 Percent Similarity: 99.40% Conservative: 2  
 Best Local Similarity: 99.40% Mismatches: 1  
 Query Match: 97.82% Indels: 0  
 DB: 21 Gaps: 0  
 US-09-765-034-2 (1-334) x AAC81122 (1-1385)  
 QY 1 MetLeuGlyIleMetAlaTrpAsnAlaIleThrCysLysAsnTrpLeuAlaIleGluAlaIle 20  
 DB 49 ATGCTGGGATCATGCGATGAAATGCMAAACTGCGTGGCAGCAGGCTGCC 108  
 QY 21 LeuGluIleValIleValIleValIleValIleValIleValIleValIleValIleValIle 40  
 DB 109 CTGGAAGAAGTACCTTCATTTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTT 168  
 QY 41 AsnThrIleValIleValIleValIleValIleValIleValIleValIleValIleValIle 60  
 DB 169 AATACCATTTGTTTACGCTACATCTCTCTCTGAAAGAACTGGAACAGCAGTAATATT 228

QY 61 TyrLeuPheAsnLeuSerValSerAspLeuAlaIlePheLeuGlySerThrLeuProMetLeuIle 80  
 DB 229 TATCTCTTAACT 288  
 QY 81 ArgSerTyrAlaAsnGlyAsnTrpIleTyrGlyAspValLeuGlyIleSerAsnArgTyr 100  
 DB 289 AGGAGTTATGCCAATGGAACTGATATATGAGACACCGCTGTCATACCAACCGCATAT 348  
 QY 101 ValLeuHisAlaAsnLeuTyrThrSerIleLeuPheLeuThrPheIleSerIleAspArg 120  
 DB 349 GTCCTTCATGCCAACCTCTATACAGCAGCATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 408  
 QY 121 TyrLeuIleIleIleIleIleIleIleIleIleIleIleIleIleIleIleIleIleIleIle 140  
 DB 409 TACTTGATATATTAATGATCTCTCTCGAGACACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 468  
 QY 141 LeuIleSerLeuAlaIleIleIleIleIleIleIleIleIleIleIleIleIleIleIleIleIle 160  
 DB 469 TTAATCTCTCTGCGCATTTGGTTTACTTAACTTAGAGTTACTACCATCTTCCCTT 528  
 QY 161 IleAsnProValIleThrAspAsnGlyThrCysAsnAspPheAlaSerSerGlyAsp 180  
 DB 529 ATAAATCCCTGTTATTAACGACAAATGGACACACCTGTAATGATTTTGCAAGTTCTGGAGAC 588  
 QY 181 ProAsnTyrAsnLeuIleIleTyrSerMetCysLeuThrLeuGlyPheLeuIleProLeu 200  
 DB 589 CCACACTACACCTCATTTACGACATGTCTACACAGTGTGGGTCTCTTATTCCTCTT 648  
 QY 201 PheValMetCysPhePheTyrTyrIleAlaLeuPheLeuGlyAsnArgGln 220  
 DB 649 TTGTGATGATGTTCTTTATTAACAAGATGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 708  
 QY 221 ValAlaIleAlaLeuProLeuGlyIleProLeuAsnLeuValIleMetAlaValIle 240  
 DB 709 GTTGCTACCTGCTCTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 768  
 QY 241 PheSerValProPheThrProTyrHisValMetArgAsnValArgIleAsnArgLeu 260  
 DB 769 TTCTCTGCTGTTTACACCTTACACCTTACACCTTACACCTTACACCTTACACCTTACACCTTAC 828  
 QY 261 GlySerTrpIleGlnIleGlnIleGlnIleGlnIleGlnIleGlnIleGlnIleGlnIleGlnIle 280  
 DB 829 GGGAGTTGGAAGCAGTACAGTACAGTACAGTACAGTACAGTACAGTACAGTACAGTACAGTACAG 888  
 QY 281 ArgProLeuAlaPheLeuAsnSerValIleAsnProValPheTyrPheLeuGlyAsp 300  
 DB 889 CG-CTTTGGCTTTCTGAAACAGTGCATCAACCGTCTCTTATTTCTTTGGAGAT 947  
 QY 301 HisPheArgAspMetLeuMetAsnGlnLeuArgHisAsnPheIleSerLeuThrSerPhe 320  
 DB 948 CACTTACGGGACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1007  
 QY 321 SerArgTrpAlaHisGlnLeuLeuLeuLeuSerPheArgGlyIle 334  
 DB 1008 AGCAGATGGGCTCATGAATCTCTTCACTTCACTTCACTTCACTTCACTTCACTTCACTTCACTT 1049  
 RESULT 7  
 ID AAT75146 standard; CDNA: 1428 BP.  
 AC AAT75146;  
 AC 07-OCT-1997 (first entry)  
 DE Human ATP receptor CDNA.  
 KW ATP receptor; G-protein coupled receptor; agonist; antagonist; ss.  
 OS Homo sapiens.  
 XX  
 XX Key location/Qualifiers  
 FT CDS 92..1096  
 FT /\*tag= a



FT	/transl_except=- (pos:725..727, aa:Ser)
FT	/transl_except=- (pos:764..766, aa:Ser)
FT	/transl_except=- (pos:820..822, Xaa)
FT	/note= "Xaa = unknown"
FT	complement (92..100)
FT	b
FT	/tag=
FT	"binding site for primer used to amplify
FT	cDNA for baculovirus expression"
FT	complement (92..109)
FT	/tag=
FT	c
FT	"binding site for primers used to amplify
FT	dNA for bacterial or COS expression"
FT	primer_bind
FT	1076..1095
FT	/tag=
FT	d
FT	"binding site for primer used to amplify
FT	eDNA for COS expression"
FT	primer_bind
FT	1079..1096
FT	/tag=
FT	e
FT	"binding site for primer used to amplify
FT	cDNA for bacterial expression"
FT	primer_bind
FT	1085..1096
FT	/tag=
FT	f
FT	"binding site for primer used to amplify
FT	cDNA for baculovirus expression"
PN	WO9724929-A1.
PD	17-JUL-1997.
XX	
XX	11-JAN-1996;
PF	96WO-US00392.
PR	11-JAN-1996;
PA	96WO-US00392.
PI	(HUMA-) HUMAN GENOME SCI INC.
PI	LA Y;
DX	WPI; 1997-372505/34.
DR	P-PADB; AAW22732.
PT	Isolated human ATP receptor - agonists and antagonists of which are
PT	useful in treatment of, e.g. asthma, hypertension, arterial
PT	thrombosis and psychotic and neurological disorders
PS	Claim 7: Fig 1A-C; 53pp; English.
XX	A cDNA clone (AAAT75146) codes for human ATP receptor (AAW22732). a
CC	polypeptide structurally related to the G protein-coupled receptor
CC	family. It was discovered in a human placenta cDNA library.
CC	cDNA encoding the mature receptor, deposited as ATCC 97333, can
CC	be expressed in bacterial (e.g. E. coli), mammalian (e.g. COS) or
CC	insect (e.g. Sf9) host cells and used to screen for agonists and
CC	antagonists useful in the treatment of a variety of disorders.
CC	It can also be used to identify a mutation in an ATP receptor gene
CC	and thus to diagnose diseases, or susceptibility to diseases,
CC	related to ATP receptor underexpression.
SQ	Sequence 1428 BP; 394 A; 308 C; 290 G; 435 T; 1 other:
Alignment Scores:	
Pred. No.:	1,78e-157 Length: 1428
Score:	1709.00 Matches: 327
Percent Similarity:	98.80% Conservative: 3
Best Local Similarity:	97.90% Mismatches: 4
Query Match:	97.82% Indels: 0
DB:	18 Gaps: 0
US-09-765-034-2 (1-334) x AAAT75146 (1-1428)	
QY	1 MetleuglylllelelalafPAsanaIarhrySLySasnrPLleuaIlaagIuaIala 20   92 ATGCTGGGAGCATCGCATGTGCACACTTGCAAAAACCTGGCTGCAGCAGAGGCTGCC 151

Qy	21	LeuGluLysTyrTyrLeuSerIlePheTyrGlyIleIleuPheValValIleValLeuGly	40
Db	152	CTGGAAAGAGTACACCTTCCATTTTATATGGAATGAGTTCCTGTGGAGATCCTTGA	211
Qy	41	AsnThrIleValValTyrGlyTyrIlePheSerLeuLysAsnTrpAsnSerSerAsnIle	60
Db	212	AATACCATTTGTGTTCACGGCTACATCTTCCTCTCGAAGAACCTGAAACAGCATATAT	271
Qy	61	TyrLeuPheAsnLeuSerValSerAspLeuAlaPheLeuGlySthrLeuProMetLeuIle	80
Db	272	TATCTCTTAACTCTCTGTCTCTGACATGCTTTCTGTGCACCTCCCTCATGCTGATA	331
Qy	81	ArgSerTyrAlaAsnGlyAsnTrpIleTyrGlyAspValLeuGlyIleSerAsnArgTyr	100
Db	332	AGGAGTTATGCCANTGGAACTGGATATATGAGACGCTCTCATATACCAACCATAT	391
Qy	101	ValLeuHisAlaAsnLeuTyrThrSerIleLeuPheLeuThrPheIleSerIleAspArg	120
Db	392	GGCTCATGGCAACCTCATACACCATCTCTTCTTCACCTTTATACCATAGATGCA	451
Qy	121	TyrLeuIleIleLysTyrProPheArgHisIleuLeuGlnIleGlySgluPheAlaIle	140
Db	452	TACTGTATATTAAGTATCCTTTCCAGAAACACCTTCGAAAAAGAAAGGTGCTATT	511
Qy	141	LeuIleSerLeuAlaIleTyrValLeuValIThrLeuGluLeuLeuProIleLeuProLeu	160
Db	512	TTAATCTCTGGCCATGTGGTATTAGTAACCTTAGATGATACCACTTCCCTT	571
Qy	161	IleAsnProValIleThrAspAsnGlyTyrThrCysAsnAspPheAlaSerSergLysP	180
Db	572	ATTAATCTGTATTAACGACAAATGGCACCACTCTGAATGATTTGCCAAGTCTGGAGAC	631
Qy	181	ProAsnTyrAsnLeuIleTyrSerMetCysLeuThrLeuLeuGlyPheLeuIleProLeu	200
Db	632	CCCACTCAACCTCATTTACAGATGTGCTAACCTGTGGGTTCCTTATTCCTT	691
Qy	201	PheValMetCysPhePheTyrTyrLysIleAlaLeuPheLeuLysGlnArgAsnArgGln	220
Db	692	TTTGATGATGTGTTTATTAACAATATGCTCTCTCTTAACAGACGAAATGAGAG	751
Qy	221	ValAlaThrAlaLeuProLeuGluLysProLeuAsnLeuValIleMetAlaValAlaIle	240
Db	752	GTTGCTACAGCTGCCCTTGAAACGCTCCACATGTCATCATGGCAGTGGTATC	811
Qy	241	PheSerValProPheThrProTyrHisValMetArgAsnValArgIleAsnArgLeu	260
Db	812	TTCTCTGTCCTTTTACACCTCATACAGCTGTGGGAAATGAGATGCTTCACAGCTG	871
Qy	261	GlySerTyrGlyGlnTyrGlnCysThrGlnValValIleAsnSerPheTyrIleValThr	280
Db	872	GGGAGTTGGACAGATACAGGACGCTCAGCTCATCACTCTTTTACATTGTGACA	931
Qy	281	ArgProLeuAlaPheLeuAsnSerValIleAsnProValPheTyrPheLeuGlnLysP	300
Db	932	CGGCTGTGGCTTCTGTGAAAGTGTATCAACCTGTCTTAATTTTCTGTGGAGAT	991
Qy	301	HisPheArgAspMetLeuMetAsnGlnLeuArgHisAsnPheLysSerLeuThrSerPhe	320
Db	992	CACCTCAGGACATCTGTATGATACATGAGACACAACCTCAAAATCCCTTACATCTTT	1051
Qy	321	SerArgTrpAlaHisGluLeuLeuLeuSerPheArgGluLys	334
Db	1052	AGCAGATGGCTCATGACTCTTACTTTCATTCAGAGAAAG	1093
RESULT 8			
ABK12957			
ID	ABK12957 standard; DNA; 1543 BP.		
AC	ABK12957;		
AC	xx		
DT	09-APR-2002 (first entry)		
DE	DNA sequence of mouse C-protein coupled receptor TGR18 gene.		



QY	25	TyLLeuSerIlePheTygIylIleGluPheValIglyValIleuGlyAsnThrIleVal	44
Db	104	TACCTCTCTGCATTTTATGCATTCGAGTTCAATTTTGGATCGCTGGGAATGTCACGTCT	163
QY	45	ValTYGlyTYrIlePheSerLeuLysAsnThrPAsnSerSerAsnIleTYrLeuPheAsn	64
Db	164	GGTGTGGGCTACCTCTTCGATCGAAGAACATGGAAACAGACAGCAATGCTATCTTTTAAAC	223
QY	65	LeuSerValSerAspIleuAlaPheLeuCYrThrIleuProMetIleuIleArgSerTYrAla	84
Db	224	CTTTCCATCTCTGACCTTGTTGTTCCGTGACACCTTCCACATCCGATTAAGAAGTTATGCC	283
QY	85	AsnGlyAsnThrPleTYrGlyAspValIleuCYsIleSerAsnArgTYrValIleuHisAla	104
Db	284	AATGATTAAGGGAGCCATTAAGATGATGTCTCTGATTAAGCAACCGATATGCTCTCACACC	343
QY	105	AsnLeuTYrThrSerIleIleuPheLeuThrPheIleSerIleAspArgTYrIleuIlele	124
Db	344	AACCTTACACCGACATCCCTTCTCTCCTACTTTCATTAGATAGGACCGAATGTGCTATG	403
QY	125	LysTYrProPheArgGluHisIleuLeuGlnLysLysGluPheAlaIleuIleSerLeu	144
Db	404	AAGTACCTTCCGAGAACACTTTCTACAAAGAAAGATTTGGCATTTTAATCTCGCTG	463
QY	145	AlaIleThrPalleuValThrIleuGluLeuLeuProIleIleuProIleAsnProVal	164
Db	464	GCTCTGGGGCTTACGACCTTAAGACCTTAAGAAAGTTCAACCATCTCATTCTCATTAATCTCTG	523
QY	165	IleThrAspAsnGlyThrTYrCYsAsnAspPheAlaSerSerGlyAspProAsnTYrAsn	184
Db	524	CCAAAGAAAGAGGCACTACTACTGCATGCATAGCAATGACAAGTTCTGGAAACCTTAACAT	583
QY	185	LeuIleTYrSerMetCYsIleuThrIleuGlyPheLeuIleProLeuPheValMetCYs	204
Db	584	CTCATTTTACACCTCTGCTGACCTTGTGGGCTTCTCTATTCCTCTCTGTGATGTGC	643
QY	205	PhePheTYrTYrLysIleAlaIlePheLeuLysGlnArgAsnArgIleValAlaThrAla	224
Db	644	TTCTTCTACTACAGATGATGATGATCTTCTTAAGAAGAGGACGACGACGACCAACACTGCC	703
QY	225	LeuProLeuGlnLysProLeuAsnIleuValIleMetAlaValAlIlePheSerValPro	244
Db	704	CTGCACATGAGCAAAACCCCAACGGCTGTGTGGTCTGGCGGTGTGTGATCTTCTCTATCTC	763
QY	245	PheThrProTYrHisValMetArgAsnValArgIleAlaSerArgIleuLysSerPlys	264
Db	764	TTCAACACCTTCATATCATGATGCGAATTTAAGATGCGCTCAGCGCTGGATGATGGCCA	823
QY	265	GlnTYrGlnCYsThrGlnValValIleAsnSerPheTYrIleValThrArgProLeuAla	284
Db	824	CAAA---GGATGTACACAGAAAGGCCCATCAATCTATATATACACTGACACGGCCTGTGCC	880
QY	285	PheLeuAsnSerValIleAsnProValPheTYrPheLeuGlnLysPheAspArgAsp	304
Db	881	TTTCTGAACAGATGCCATCAACCCATCTTACTTCTCTATGGGAACCATTAACAGAGAG	940
QY	305	MetLeuMetAsnGlnIleuArgHisAsnPheLysSerLeuThrSerPhe	320
Db	941	ATGCTGATTAAGTACGACATACTTCAAGTCCCTTACATCTTTC	988
RESULT 9			
AAS18599			
ID AAS18599 standard; DNA: 6721 BP.			
XX AAS18599;			
XX 12-MAR-2002 (first entry)			
XX Purinergic receptor P2Y, G-protein coupled 1 gene.			
XX Purinergic receptor P2Y, G-protein coupled 1; P2RY1; anticoagulant;			
KW coagulant; platelet aggregation; haplotyping; drug screening;			

[illegible]

```
Db 4610 CGACACACCTGAGACAGTACCTGCGAAGTATTTCATCTACAGCATGTGACGACCGT 4669
Oy 193 uleuuglypHeuLeuProLeuPheValMet-----CysPhePheTyrTyrIleAl 211
Db 4670 GGCCATGTTCTGTGTCCTTGGTGTCTGATCTGCGCTTACGCAATTAATCTGAGAC 4729
Oy 211 aleuPheLeuYsGlnAArgAsnArgGlnValAlaThrAlaLeuProLeu---GluLysPr 230
Db 4730 TTGTATTTCACAAAGATCTGACACATCT-----CCCTGAGAGGAAATAC 4774
Oy 230 oleuAsnLeuValIleleAlaValValIlePheSerValProPheThrProTyrHisVa 250
Db 4775 GATTTACCTGGTAATCATCTGACTGCTTTTGGTGTCTTACATCCCTTTCATGT 4834
Oy 250 lleArGAsnValArgIleAlaSerArgLeuGlySerTPrLysGlnTyrGlnCysThr-- 269
Db 4835 GATGAAAGAGATGAACTTGAAGGCCCGGCTTGATTTTCAGACCCCGACGCAATGTCTT 4894
Oy 270 -GlnValValIleAsnSerPheTyrIleValThrArgProLeuAlaPheLeuAsnSerVa 289
Db 4895 CAATGACAGAGGTTTATGCGACGATCATGACAAAGAGGTTAGCAAGTCTCAACAGTTG 4954
Oy 289 lleAsnProValPheTyrPheLeuLeuGlyAspHisPheArgAspMetLeuMetAsnGl 309
Db 4955 TGTGAGCCCATCTCTATTTCTGTGGGGAGATACTTTCAGAAAGAGACTCTCCGAGC 5014
Oy 309 nleuArg 311
Db 5015 CACMAG 5021

RESULT 10
AAS18600
ID AAS18600 standard; DNA; 6721 BP.
XX
AC AAS18600;
XX
DT 12-MAR-2002 (first entry)
XX
DE Purinergic receptor P2Y, G-protein coupled 1 gene, generic sequence.
XX
KW Purinergic receptor P2Y, G-protein coupled 1; P2RY1; anticoagulant;
KW coagulant; platelet aggregation; haplotyping; drug screening;
KW transgenic animal; human; ds.
XX
OS Homo sapiens.
XX
PN WO200190117-A2.
XX
PD 29-NOV-2001.
XX
PF 21-MAY-2001; 2001WO-US16432.
XX
PR 19-MAY-2000; 2000US-205996P.
XX
PA (GENA-) GENA155ANCE PHARM INC.
XX
PI Kazemi A, Koshy B, Tanguay DA;
XX
DR WPI; 2002-083074/11.
XX
PT New purinergic receptor P2Y G-protein coupled 1 (P2RY1) gene
PT polymorphic variants, useful e.g. in studying the expression and
PT function of P2RY1 and screening candidate drugs for treating diseases
PT related to P2RY1 activity
XX
PS Claim 20; Page 77-79; 79pp; English.
XX
CC The invention relates to a novel isolated polypeptide comprising a
CC sequence which is a polymorphic variant of a reference sequence for the
CC purinergic receptor P2Y, G-protein coupled, 1 (P2RY1) protein or its
CC fragment. The polymorphic variant comprises one or more variant amino
CC acids selected from valine at a position 34 and glycine at a position
```

```
CC 262. The polymorphic variants are useful in studying the expression
CC and function of P2RY1, in expressing P2RY1 protein for use in screening
CC for candidate drugs to treat diseases related to P2RY1 activity, in
CC studying the effect of the variation on the biological activity of
CC P2RY1, and the binding affinity of candidate drugs targeting P2RY1 for
CC the treatment of disorders related to platelet aggregation. The
CC haplotyping methods are useful in validating P2RY1 as a candidate
CC target for treating a specific condition or disease predicted to be
CC associated with P2RY1 activity, or in the design of clinical trials of
CC candidate drugs for treating a specific condition or disease associated
CC with P2RY1 activity. The transgenic animals are useful for studying
CC expression of the P2RY1 isogenes in vivo, for in vivo screening and
CC testing of drugs targeted against P2RY1 protein, and for testing the
CC efficacy of therapeutic agents and compounds for disorders related to
CC platelet aggregation in a biological system. The present sequence
CC represents the generic coding sequence of human purinergic receptor P2Y,
CC G-coupled protein 1 (P2RY1), incorporating all possible polymorphisms of
CC the gene.
XX
SQ Sequence 6721 BP; 1904 A; 1539 C; 1558 G; 1682 T; 38 other;
XX
Alignment Scores:
Pred. No.: 1,09e-37 Length: 6721
Score: 493.00 Matches: 116
Percent Similarity: 54.18% Conservative: 59
Best Local Similarity: 35.91% Mismatches: 131
Query Match: 28.22% Indels: 17
DB: 24 Gaps: 7
US-09-765-034-2 (1-334) x AAS18600 (1-6721)
Oy 1 MetLeuGlyIleMetAlaThrPAsnAlaThrCysLysAsnTrpLeuAlaIleAla 20
Db 4070 GTTCCTGGGGAAACAGACAGCGTGCCTCCACATCGCGCGTCTCTGCTCAATGACG 4129
Oy 20 aleuGluLys-----TyrTyrLeuSerIlePheTyrGlyIleGluPheVa 35
Db 4130 CTGGACSAAGACGGCGTCCAGTTTATCTTACCTGCGGCGTGTCTGATCTTGGTATTCAT 4189
Oy 35 lValGlyValIleuGlyAsnThrIleValValTyrGlyTyrIlePheSerLeuAsnTr 55
Db 4190 CATGGCTTCTTCGGCAACAGCGTGCATCTGATGTTCTTCCATCATGAAACCCCTG 4249
Oy 55 pAsnSerSerAsnIleTyrLeuPheAsnLeuSerValSerAspLeuAlaPheLeuGlyTh 75
Db 4250 GAGCGGCATCTCCGTGATACATGTTTGGCTGTGGCGCACTTCTGTAGCTGTGAC 4309
Oy 75 rleuProMetLeuIleArgSerTyrAlaAsn---GlyAsnTrpIleTyrGlyAspVal 94
Db 4310 TCTGCCAGCGCTGATCTTCTACTACTCAATAAACAAGACATGATCTCGGCGATCAT 4369
Oy 94 ucYsIleSerAsnArgTyrValLeuHisAlaLeuIleTyrThrSerIleLeuPheLeuTh 114
Db 4370 GTGTAAACTGCAGAGGTTTATCTTTCATGTGAACCTCTATGGCAGCATCTGTCTGCAC 4429
Oy 114 rPheIleSerIleAspArgTyrLeuIleIleLysTyrPropheArgGluHisLeuLeuGl 134
Db 4430 ATCATCATGAGCCAGCCAGCGTACAGCGTGGTGGTACCCCTCAATCCCTGGCGCGGT 4489
Oy 134 nLysLysGluPheAlaIleLeuIleSerLeuAlaIleTyrValLeuValThrLeuGluLe 154
Db 4490 CAAAGAAAGAAATGATCTGTATCAAGCGTGCATGCTGATGCTGATGCTGCGCAT 4549
Oy 154 uleuPProIleLeuProLeuIleAsnProValIleThrAspAsnGlyThr---ThrcysAs 173
Db 4550 CTCCCCATCTCTTCTACTCAGTACCGGCGTCCCAAAACAAACATCATCTCTGTTA 4609
Oy 173 nAspPheAlaSerSerGlyAspProAsnTyrAsnLeuIleTyrSerMetCysLeuThrIle 193
Db 4610 CGACACACCTGAGACAGTACCTGCGAAGTATTTCATCTACAGCATGTGACGACCGT 4669
Oy 193 uleuGlyPheLeuIleProLeuPheValMet-----CysPhePheTyrTyrIleAl 211
```







ABN85630  
ID ABN85630 standard; DNA; 1014 BP.  
AC ABN85630;  
XX  
XX  
18-SEP-2002 (first entry)  
DE Human P2Y-1like receptor variant encoding gene SEQ ID NO 3.  
XX  
XX Human; P2Y-1like receptor; HIPHM 0000037; immunity; inflammation;  
KW cancer; Crohn's disease; irritable bowel syndrome; rheumatoid arthritis;  
KW immunomodulator; anti-inflammatory; cytostatic; antispasmodic;  
KW gastrointestinal; anti-ulcer; antirheumatic; antithrombotic; virocidic;  
KW antibacterial; immunosuppressive; dermatological; nephrotoxic;  
KW antiallergic; analgesic; receptor; gene; ds.  
XX  
OS Homo sapiens.  
FH Key Location/Qualifiers  
FT 1..1014  
FT CDS /tag= a  
FT /product= "P2Y-1like receptor variant"  
XX  
XX GB2369364-A.  
XX  
XX  
XX 29-MAY-2002.  
XX  
XX 31-AUG-2001; 2001GB-0021215.  
XX  
XX 01-SEP-2000; 2000GB-0021524.  
XX 06-SEP-2000; 2000GB-0021894.  
XX 25-SEP-2000; 2000GB-0023444.  
XX  
XX (GLAXO ) GLAXO GROUP LTD.  
XX  
XX Food SM, Ignar DM;  
XX  
XX WPI; 2002-511268/55.  
XX P-PSDB; AB883819.  
XX  
XX  
XX An isolated P2Y-1like receptor polypeptide (HIPHM 0000037) which can be  
PT used for the identification of agonists and antagonists which may be  
PT used to treat an immune or inflammatory disease -  
XX  
XX Claim 5; Page 28-29; 35pp; English.  
XX  
XX The invention relates to an isolated P2Y-1like receptor polypeptide  
CC (AB883818-AB883819) which is also referred to in the specification as  
CC HIPHM 0000037. An effective amount of a substance (agonist or  
CC antagonist) which modulates P2Y receptor activity is useful to treat a  
CC subject having a disorder that is responsive to P2Y-1like receptor  
CC modulation. The disorder is a disease of immunity or inflammation. The  
CC substance may also be used to manufacture a medicine for the treatment or  
CC prophylaxis of a disorder that is responsive to stimulation or modulation  
CC of P2Y-1like receptor activity. Disorders which may be treated include  
CC colon cancers, asthma, COPD, Crohn's disease, irritable bowel syndrome,  
CC gastroenteritis and colitis, inflammatory bowel syndrome, ulcerative  
CC colitis, rheumatoid arthritis, viral diseases, bacterial infections,  
CC autoimmune diseases, dermatitis, glomerulonephritis allergies, allergic  
CC rhinitis, inflammatory pain and general inflammation such as tendonitis,  
CC polyarthritis or prostatitis. The invention provides alternative  
CC substances for the treatment of immunological and inflammatory diseases.  
CC The present sequence is that the P2Y-1like receptor variant encoding gene  
CC of the invention.  
XX  
XX Sequence 1014 BP; 258 A; 263 C; 189 G; 304 T; 0 other;  
SO

Alignment Scores:  
Pred. No.: 3,3e-37  
Score: 477.00  
Percent Similarity: 55.88%  
Best Local Similarity: 35.95%  
Query Match: 27, 30%  
Matches: 110  
Mismatches: 61  
Indels: 12

DB: 24 Gaps: 6  
US-09-765-034-2 (1-334) x ABN85630 (1-1014)  
QY 8 AsnAlaThrCysLysAsnTrpLeuAlaAlaGluAlaLeuGluLysTrpTyrLeuSer 27  
DB 67 AATTGCATCTGATAAAC-----ATCCCACTCAAGATGACCTACTCTCT 111  
QY 28 IlePheTyrGlyIleGluPheValAlaGlyValLeuGluLysAsnThrIleValAlaTyrGly 47  
DB 112 GTTATTATATGCAATTAATCTCCCTGCGATTCGAGATTCGACATGATGATATCAGT 171  
QY 48 TyrIlePheSerLeuLysAsnTrpAsnSerSerAsnIleTyrLeuPheAsnLeuSerVal 67  
DB 172 TACATTTTCAAAATGACACCTTGGAAGAGAGACCACTTCATGTCGAGCTGGGCTG 231  
QY 68 SerAspLeuAlaPheLeuCysThrLeuProMetLeuIleArgSerTyrAlaAsnGly--- 86  
DB 232 ACAGATCTGCTGATATCGACACAGCTCCCTCTCTGATTCACATGACGACGCGGA 291  
QY 87 AsnTrpIleTyrGlyAspValLeuCysIleSerAsnArgTyrValLeuHisAlaAsnLeu 106  
DB 292 AACTGATCTTTGGAGATTCATGATGTAAGTTATCCGCTTCAGCTTCATTCACACTG 351  
QY 107 TyrThrSerIleLeuPheLeuThrPheIleSerIleAspArgTyrLeuIleIleLysTyr 126  
DB 352 TATAGCAGCATCCCTCTCCCTGACCTGTTTCAGATCTTCGCTGATGATTCATTCAC 411  
QY 127 ProPheArgLysIleLeuGluLysGluPheAlaIleLeuIleSerLeuAlaIle 146  
DB 412 CCATAGCTGCTGTTTCCATTCACAAACGATGATGATGATGATGATGATGATGATG 471  
QY 147 TrpValLeuValThrLeuGluLeuProIleLeuProLeuIleAsnProValIleThr 166  
DB 472 TGATCATTTTCACGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 531  
QY 167 AspAsnGlyThrThrCysAsnAspPheAlaSerSerLysProAsnTyrAsnLeuIle 166  
DB 532 ACCAAGACATCAGCTCTGACCTGACCTGACCTGACCTGACCTGACCTGACCTGAC 591  
QY 187 TyrSerMetCysLeuThrLeuLeuGlyPheLeuIleProLeuPheValMetCysPhePhe 206  
DB 592 TACAACTGATTTTGCATGACATGATGATGATGATGATGATGATGATGATGATGATG 651  
QY 207 TyrTyrIleValAlaLeuPheLeuLysGluArgAsnArgLysValAlaThrAlaLeuPro 226  
DB 652 TATACACGATTT---ATCCACACTGTCGACCTGACCTGACCTGACCTGACCTGAC 708  
QY 227 LeuGluLysProLeuAsnLeuValIleMetAlaValAlaIlePheSerValProPheThr 246  
DB 709 ---CAGAAAGCAGACAGGCTAACCATTCCTGCTGCTGCTGCTGCTGCTGCTGCT 765  
QY 247 ProTyrHisValMetArgAsnValArgIleAlaSerArgLeuGlySerTyrPlyGlnTyr 266  
DB 766 CCCTTCATATCTTGAAGGATGATGATGATGATGATGATGATGATGATGATGATGAT 816  
QY 267 GlnCysThr---GlnValValIleAsnSerPheTyrIleValThrArgProLeuAlaPhe 285  
DB 817 AGTTGTTCCATTGGAATGATGATGATGATGATGATGATGATGATGATGATGATG 876  
QY 286 LeuAsnSerValIleAsnProValPheTyrPheLeuGluLysAspHisPheArgAspMet 305  
DB 877 CTGACACCTTTGGTATACCTGTTACTATATGTTGGTGTGACGACACATTCACGAC 936  
QY 306 LeuMetAsnGlnLeuArg 311  
DB 937 GTCTGCTCAACAGTGA 954  
RESULT 15  
AAD34278  
ID AAD34278 standard; cDNA; 1014 BP.  
XX  
XX AAD34278;  
AC



XX 16-JUL-2002 (first entry)  
 XX XX Human AXOR89 (G-protein coupled receptor) cDNA.  
 KW Human: AXOR89 polypeptide; G-protein coupled receptor; vaccine; receptor;  
 KW infection; cancer; pain; asthma; Parkinson's disease; diabetes; obesity;  
 KW anorexia; bulimia; acute heart failure; hypotension; hypertension; ulcer;  
 KW stroke; urinary retention; osteoporosis; angina pectoris; schizophrenia;  
 KW myocardial infarction; allergy; benign prostatic hyperplasia; migraine;  
 KW vomiting; psychotic; neurological disorder; anxiety; manic depression;  
 KW delirium; Huntington's Disease; Gilles de la Tourette's syndrome;  
 KW dementia; dyskinesia; gene; ss.  
 XX OS Homo sapiens.  
 XX FH Key Location/Qualifiers  
 XX FT CDS 1..1014  
 XX FT /\*tag= a  
 XX FT /product= "Human AXOR89 protein"  
 XX GB2365012-A.  
 XX 13-FEB-2002.  
 XX 10-MAY-2001; 2001GB-0011437.  
 XX 11-MAY-2000; 2000US-0569137.  
 XX (SMIK ) SMITHKLINE BEECHAM CORP.  
 XX (SMIK ) SMITHKLINE BEECHAM PLC.  
 XX PI Elshourbagy N, Shabon U;  
 XX WPI: 2002-332558/37.  
 XX P-PSDB: AAE21803.  
 XX Novel AXOR89 polypeptide and polynucleotide encoding it, useful for  
 XX identifying agonists and antagonists in the treatment of diseases  
 XX associated with an AXOR89 imbalance, such as cancers, diabetes or  
 XX asthma -  
 XX Claim 2; Page 30; 37pp; English.  
 XX The invention relates to an isolated AXOR89 polypeptide (G-protein  
 XX coupled receptor) and its polynucleotide. The novel AXOR89 polypeptide  
 XX and polynucleotide encoding the polypeptide, is useful for identifying  
 XX agonists and antagonists (or inhibitors) that are potentially useful in  
 XX treating conditions associated with an AXOR89 imbalance, such as  
 XX bacterial, fungal or protozoan infections, cancers, pain, asthma,  
 XX Parkinson's Disease, diabetes, obesity, anorexia, bulimia, acute heart  
 XX failure, hypotension, hypertension, urinary retention, osteoporosis,  
 XX angina pectoris, myocardial infarction, stroke, ulcers, allergies, benign  
 XX prostatic hyperplasia, migraine, vomiting, psychotic and neurological  
 XX disorders, anxiety, schizophrenia, manic depression, delirium, dementia,  
 XX dyskinesias, such as Huntington's Disease or Gilles de la Tourette's  
 XX syndrome. The polynucleotide sequence may also be used for chromosome  
 XX localisation or tissue expression studies. The AXOR89 is used as a  
 XX vaccine or to produce fusion proteins. The present sequence is human  
 XX AXOR89 cDNA.  
 XX SQ Sequence 1014 BP; 259 A; 263 C; 188 G; 304 T; 0 other;  
 XX  
 XX Alignment Scores:  
 XX Pred. No.: 3.3e-37 Length: 1014  
 XX Score: 477.00 Matches: 110  
 XX Percent Similarity: 55.88% Conserved: 61  
 XX Best Local Similarity: 35.95% Mismatches: 123  
 XX Query Match: 27.30% Indels: 12  
 XX DB: 24 Gaps: 6  
 XX US-09-765-034-2 (1-334) x AAD34278 (1-1014)

QY 8 AsnAlaThrCysLysAsnTrpLeuAlaAlaGluAlaLeuGluLysTyrTyrLeuSer 27  
 Db 67 AATTCGACGATGAGAAAC-----ATCCACATCAAGTGCATCTACCTCCT 111  
 QY 28 IlePheTyrGlyIleGluPheValValGlyValLeuGlyAsnThrIleValValTyrGly 47  
 Db 112 GTTATTATGAGCATATATCTCTCTGAGGATTTCCAGGCAATGCGATGATATCCACT 171  
 QY 48 TyrIlePheSerLeuLysAsnTrpAsnSerSerAsnIleTyrIlePheAsnLeuSerVal 67  
 Db 172 TACATTTTCAAAATAGACCTTGGAAGACACACACATCATATGCTGAACTGGCCGCG 231  
 QY 68 SerAspLeuAlaPheLeuCysThrLeuPrometLeuIleTyrSerTyrAlaAsnLys 86  
 Db 232 ACAGATCTGCTGATCTGACGACCTCCCTCTGATTCATCTACTATGCTAGTGGCGAA 291  
 QY 87 AsnTrpIleTyrGlyAspValLeuCysIleSerAsnArgTyrValLeuHisAlaLeu 106  
 Db 292 AACTGATCTTGGAGATTTTCATGTGATTAATCCGCTTACGCTTCATTCAACTG 351  
 QY 107 TyrThrSerIleLeuPheLeuThrPheIleSerIleAspArgTyrLeuIleLysTyr 126  
 Db 352 TATACAGACATCT 411  
 QY 127 ProPheArgGluHisLeuLeuGluLysGluPheAlaIleLeuIleSerLeuAlaIle 146  
 Db 412 CCAATGAGCTGCTTTCCATTCATTCACAAACCTGATGCAAGTGTGCTGCTGCTG 471  
 QY 147 TrpValLeuValThrLeuGluLeuLeuProIleLeuProIleAsnProValIleThr 166  
 Db 472 TGATCATTTTACCTGATGCTGATGCTGATGCTGATGCTGATGCTGATGCTGATG 531  
 QY 167 AspAsnGlyThrThrCysAsnAspPheAlaSerSerGlyAspProAsnTyrAsnLeuIle 186  
 Db 532 ACCAAGACATGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 591  
 QY 187 TyrSerMetCysLeuThrLeuLeuGluLysLeuIlePheLeuValMetCysPhe 206  
 Db 592 TACAACTTAATTTTACGCAACTACTTCTGCTGCTGCTGCTGCTGCTGCTGCTG 651  
 QY 207 TyrTyrIleValIleAlaLeuPheLeuLysGlnArgAsnArgGlnValAlaThrAlaLeuPro 226  
 Db 652 TATACACAGATTT--ATCCACACTGTCGACCATGACGCAAAACGACAGCTGCTTAA 708  
 QY 227 LeuGluLysProLeuAsnLeuValIleMetAlaValIlePheSerValProPheThr 246  
 Db 709 --CAGAAAGCAGCAGAGCTTACCACTTCTGCTGCTGCTGCTGCTGCTGCTGCT 765  
 QY 247 ProTyrHisValMetArgAsnValArgIleAlaSerArgLeuGlySerTrpLysGlnTyr 266  
 Db 766 CCTTCATATCTTGAAGGTCATTTGCGATCCGATCTGCTGCTGCTGCTGCTGCTG 816  
 QY 267 GlnCysThr--GlnValValIleAsnSerPheTyrIleValThrArgProLeuAlaPhe 285  
 Db 817 AGTTTTCATTAATGAAATCAGATCATGATGATGATGATGATGATGATGATGATGAT 876  
 QY 286 LeuAsnSerValIleAsnProValPheTyrPheLeuLeuGlyAspHisPheArgAspMet 305  
 Db 877 CTGAACACCTTTGTTAACTGTTACTATATGTGTGTGTCAGACGAACTTTCAGAGGCT 936  
 QY 306 LeuMetAsnGlnLeuArg 311  
 Db 937 GTCTGCTCAACAGTGAGA 954  
 Search completed: December 9, 2002, 12:22:56  
 Job time : 290 secs